Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 124. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-10-01 to 2023-10-01.)
ArticleCitations
An interactive web-based dashboard to track COVID-19 in real time7266
Estimates of the severity of coronavirus disease 2019: a model-based analysis2568
Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study2428
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study2368
Early dynamics of transmission and control of COVID-19: a mathematical modelling study1632
Viral load of SARS-CoV-2 in clinical samples1265
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study1210
Viral dynamics in mild and severe cases of COVID-191186
A minimal common outcome measure set for COVID-19 clinical research977
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial964
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study873
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics849
Clinical and virological data of the first cases of COVID-19 in Europe: a case series844
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial818
Real estimates of mortality following COVID-19 infection818
COVID-19: combining antiviral and anti-inflammatory treatments810
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Co795
Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study795
Convalescent plasma as a potential therapy for COVID-19716
A clinical case definition of post-COVID-19 condition by a Delphi consensus633
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study629
Scientific and ethical basis for social-distancing interventions against COVID-19621
Clinical features and management of human monkeypox: a retrospective observational study in the UK620
Can we contain the COVID-19 outbreak with the same measures as for SARS?614
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study585
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study568
Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study534
Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study520
COVID-19 and multisystem inflammatory syndrome in children and adolescents518
Genomic evidence for reinfection with SARS-CoV-2: a case study506
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study500
The value of antimicrobial peptides in the age of resistance478
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance477
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study473
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study457
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study456
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study455
Asymptomatic cases in a family cluster with SARS-CoV-2 infection434
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study431
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2420
A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation389
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study382
COVID-19 and medical education374
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical 363
Stigma during the COVID-19 pandemic344
Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series338
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, mult332
The many estimates of the COVID-19 case fatality rate328
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study325
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study320
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries319
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study317
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study307
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison291
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 291
Exaggerated risk of transmission of COVID-19 by fomites288
The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017267
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study267
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial263
The COVID-19 infodemic260
COVID-19 pneumonia: what has CT taught us?249
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis248
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people240
Serology testing in the COVID-19 pandemic response234
Smell and taste dysfunction in patients with COVID-19233
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England224
Long-term consequences of COVID-19: research needs220
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised217
Taking the right measures to control COVID-19214
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT211
Covert COVID-19 and false-positive dengue serology in Singapore210
Scaling up COVID-19 rapid antigen tests: promises and challenges208
SARS-CoV-2: virus dynamics and host response206
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial206
Willingness to vaccinate against COVID-19 in Australia203
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial201
Connecting clusters of COVID-19: an epidemiological and serological investigation200
Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial197
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data191
Open access epidemiological data from the COVID-19 outbreak188
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study187
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial186
COVID-19 in Latin America184
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-cont182
COVID-19 in children: the link in the transmission chain182
Intention to vaccinate against COVID-19 in Australia181
Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study179
Monitoring approaches for health-care workers during the COVID-19 pandemic176
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis175
Likelihood of survival of coronavirus disease 2019171
The important role of serology for COVID-19 control170
The indirect impact of COVID-19 on women170
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study170
What reinfections mean for COVID-19163
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical tri162
Current gaps in sepsis immunology: new opportunities for translational research161
Baricitinib for COVID-19: a suitable treatment?161
COVID-19 with spontaneous pneumomediastinum161
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study160
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design160
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study158
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial157
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study157
The first 2019 novel coronavirus case in Nepal156
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19154
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis152
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity148
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study147
Global shortage of personal protective equipment147
The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later145
Antimalarial drug resistance in Africa: the calm before the storm?145
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard143
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden142
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study142
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial141
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study141
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study139
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis137
The global incidence and diagnosis of fungal keratitis137
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study136
Guidelines for pregnant women with suspected SARS-CoV-2 infection134
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study132
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression127
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis126
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis124
0.021510124206543